Altimmune, Inc. (ALT)
NASDAQ$5.2-0.35 (-6.31%)
Market Cap
$427.43M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
441 of 925
Rank in Industry
261 of 528
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
ALT Insider Trading Activity
ALT Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $110,547 | 1 | 100 |
Related Transactions
| Drutz David | director | 0 | $0 | 1 | $110,547 | $-110,547 |
About Altimmune, Inc.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known …
Insider Activity of Altimmune, Inc.
Over the last 12 months, insiders at Altimmune, Inc. have bought $0 and sold $110,547 worth of Altimmune, Inc. stock.
On average, over the past 5 years, insiders at Altimmune, Inc. have bought $7.62M and sold $897,547 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 300 shares for transaction amount of $863 was made by Drutz David (director) on 2023‑08‑15.
List of Insider Buy and Sell Transactions, Altimmune, Inc.
| 2024-08-19 | Sale | Drutz David | director | 16,011 0.0206% | $6.90 | $110,547 | -8.42% | |
| 2023-08-15 | Drutz David | director | 300 0.0006% | $2.88 | $863 | +145.20% | ||
| 2023-03-24 | Eisenstadt Richard I | Chief Financial Officer | 10,000 0.0213% | $4.31 | $43,140 | -5.32% | ||
| 2023-03-23 | Harris Matthew Scott | Chief Medical Officer | 10,000 0.0215% | $4.22 | $42,200 | -2.39% | ||
| 2023-03-23 | Drutz David | director | 9,000 0.0195% | $4.27 | $38,430 | -2.39% | ||
| 2022-12-22 | Sale | Pisano Wayne | director | 20,000 0.0383% | $15.01 | $300,268 | -73.88% | |
| 2022-08-30 | Sale | Garg Vipin K | President and CEO | 20,000 0.0429% | $20.02 | $400,322 | -47.31% | |
| 2022-08-12 | Sale | Garg Vipin K | President and CEO | 15,000 0.0264% | $15.06 | $225,890 | -39.92% | |
| 2022-08-12 | Sale | GILL JOHN | director | 2,714 0.0048% | $15.00 | $40,710 | -39.92% | |
| 2022-07-01 | Sale | Roberts M Scot | Chief Scientific Officer | 10,182 0.022% | $12.00 | $122,184 | +0.62% | |
| 2022-06-29 | Sale | Roberts M Scot | Chief Scientific Officer | 5,462 0.0117% | $12.00 | $65,546 | -3.74% | |
| 2022-06-27 | Sale | Roberts M Scot | Chief Scientific Officer | 37,352 0.0803% | $12.00 | $448,254 | -3.40% | |
| 2022-06-27 | Sale | Jorkasky Diane | 17,610 0.0371% | $11.75 | $206,944 | -3.40% | ||
| 2022-06-15 | Drutz David | 1,000 0.002% | $8.00 | $8,000 | +36.66% | |||
| 2022-05-24 | Drutz David | 1,200 0.0024% | $4.50 | $5,400 | +140.89% | |||
| 2022-02-28 | Sale | Harris Matthew Scott | Chief Medical Officer | 30,000 0.0692% | $7.52 | $225,600 | +52.50% | |
| 2021-03-01 | Sale | Hodges Philip | director | 6,000 0.0151% | $16.08 | $96,480 | -28.09% | |
| 2020-12-10 | Schafer Klaus | director | 2,000 0.0076% | $11.99 | $23,980 | +5.50% | ||
| 2020-12-01 | Sale | Hodges Philip | director | 1,227 0.0047% | $13.54 | $16,614 | -6.30% | |
| 2020-11-30 | Sale | Hodges Philip | director | 2,500 0.0096% | $12.00 | $30,000 | +6.26% |
Total: 148
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Drutz David | director | 41958 0.0545% | $232,866.90 | 6 | 1 | +43.65% |
| PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | 10 percent owner | 6626403 8.6042% | $36.78M | 1 | 3 | |
| EVNIN LUKE | 10 percent owner | 6347614 8.2422% | $35.23M | 2 | 0 | |
| MPM BIOVENTURES III LLC | 10 percent owner | 6347614 8.2422% | $35.23M | 2 | 0 | |
| Venrock Healthcare Capital Partners III, L.P. | 10 percent owner | 4500000 5.8431% | $24.98M | 4 | 0 | +64.5% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$14,527,743 | 76 | 38.40% | $446.21M | |
$84,871,118 | 57 | 17.71% | $416.77M | |
Altimmune, Inc. (ALT) | $24,384,691 | 42 | -30.27% | $427.43M |
$54,828,550 | 26 | -13.88% | $421.09M | |
$26,923,982 | 20 | -17.22% | $432.57M |
ALT Institutional Investors: Active Positions
| Increased Positions | 102 | +58.29% | 5M | +13.58% |
| Decreased Positions | 69 | -39.43% | 4M | -10.63% |
| New Positions | 38 | New | 870,626 | New |
| Sold Out Positions | 24 | Sold Out | 1M | Sold Out |
| Total Postitions | 208 | +18.86% | 41M | +2.95% |
ALT Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $40,959.00 | 8% | 6.16M | +693,211 | +12.68% | 2024-12-31 |
| Ameriprise Financial Inc | $34,945.00 | 6.83% | 5.25M | +1M | +35.57% | 2024-12-31 |
| Vanguard Group Inc | $29,470.00 | 5.76% | 4.43M | -552,246 | -11.08% | 2024-12-31 |
| State Street Corp | $23,076.00 | 4.51% | 3.47M | +56,190 | +1.65% | 2024-12-31 |
| Tang Capital Management Llc | $18,288.00 | 3.57% | 2.75M | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $11,029.00 | 2.15% | 1.66M | -9,498 | -0.57% | 2024-12-31 |
| Knoll Capital Management, Llc | $7,458.00 | 1.46% | 1.12M | 0 | 0% | 2024-12-31 |
| Bellevue Group Ag | $6,287.00 | 1.23% | 945,446 | +81,786 | +9.47% | 2024-12-31 |
| Morgan Stanley | $6,130.00 | 1.2% | 921,822 | -373,763 | -28.85% | 2024-12-31 |
| Ubs Group Ag | $4,785.00 | 0.93% | 719,555 | +437,100 | +154.75% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.